Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

PurposeProstate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer.ProceduresBiodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM.ResultsNo major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi).Conclusions[18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.

[1]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[2]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[4]  S. Larson,et al.  Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. , 2001, Archives of internal medicine.

[5]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[6]  R B Jeffrey,et al.  Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. , 1987, Radiology.

[7]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[8]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  P. Scardino,et al.  The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. , 1989, The Journal of urology.

[10]  George Sgouros,et al.  Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[11]  M. Hultcrantz,et al.  Limited evidence for the use of imaging to detect prostate cancer: a systematic review. , 2014, European journal of radiology.

[12]  Mithat Gonen,et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  E. Demirci,et al.  68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  F. Fazio,et al.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. , 2007, European urology.

[15]  J. Pruim,et al.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. , 2003, European urology.

[16]  C. Greco,et al.  Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? , 2008, Prostate Cancer and Prostatic Diseases.

[17]  Zhen Cheng,et al.  One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  D. Lee,et al.  Physical performance comparison of Ga-68 and F-18 in small animal PET system , 2010 .

[19]  A. Cuthbertson,et al.  One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester ([(18)F]F-Py-TFP): a new prosthetic group for efficient labeling of biomolecules with fluorine-18. , 2010, Journal of medicinal chemistry.

[20]  P. Carroll,et al.  The relative impact and future burden of prostate cancer in the United States. , 2004, The Journal of urology.

[21]  A. Scott,et al.  Positron emission tomography and molecular imaging of the prostate: an update , 2006, BJU international.

[22]  S. Reske,et al.  Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep , 2014, Pharmaceuticals.

[23]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[25]  U. Haberkorn,et al.  PSMA as a target for radiolabelled small molecules , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  A. Horwich,et al.  2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[28]  Wesley E. Bolch,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[29]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[30]  C. Kwak,et al.  Ureteral stenting after ureteroscopy for ureter stones: A prospective randomised study assessing symptoms and complications , 2003 .

[31]  B. Hadaschik,et al.  I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014 .

[32]  R. Freudenberg,et al.  Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III. , 2014, Nuklearmedizin. Nuclear medicine.

[33]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[34]  M. Stabin,et al.  MIRD Pamphlet No. 14: a dynamic urinary bladder model for radiation dose calculations. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  F Fazio,et al.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.

[36]  T. Holland-Letz,et al.  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[38]  J. Seidel,et al.  N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-l-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer , 2008, Clinical Cancer Research.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[40]  H. M. Deloar,et al.  Internal absorbed dose estimation by a TLD method for 18F-FDG and comparison with the dose estimates from whole body PET. , 1999, Physics in medicine and biology.

[41]  A. Kozikowski,et al.  A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. , 2009, Journal of medicinal chemistry.

[42]  Wang Xing-sheng,et al.  Overview of Prostate-specific Membrane Antigen , 2010 .

[43]  T. Block,et al.  Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy , 1999, European Urology.

[44]  G. Sauter,et al.  Prostate‐specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique , 2007, Histopathology.

[45]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.